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Thanks to the sponsors… 
The organisers would like to thank the following companies for their support 
towards this event –  
 
 
 
 
 
 
Note - Sanofi Pasteur MSD has provided an unrestricted educational grant to 
this workshop.  They have not had any input into the arrangements or           
content of the workshop. The same also applies for GlaxoSmithKline 
Vaccines and Wyeth Vaccines. 
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About this event 
            
This workshop was organised by the Infectious Disease Research Network 
(IDRN) with the scientific programme developed by the Liverpool School of 
Tropical Medicine and University College London. In particular, the IDRN 
would like to acknowledge the efforts of Adam Wright and Stephen Gordon 
(Liverpool), and Jeremy Brown (UCL). 
 
We would also like to acknowledge the input of the speakers and workshop 
delegates in making the day such a success. 
 
The aims of this workshop were to 
 
• Identify priority areas for research focusing on the human mucosal 
respiratory immune response towards pneumococcal 
colonisation/infection 
• Foster collaborations between research leaders for a focussed multi-
disciplinary approach towards the development of novel interventions that 
will improve outcome for patients in the short and long term 
• Lead to measurable outcomes in the form of funding 
proposals/submissions and published proceedings. The journal ‘Vaccine’ 
have indicated they would be keen to publish the proceedings of this 
meeting. 
 
Post-workshop resource 
The IDRN have created a webpage containing most of the presentations from 
the event, notes from the discussions, and also an email list of those who 
attended the workshop. 
 
This resource is available at http://idrn.org/events/previous/pneumococci.php  
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Mucosal perspectives in pneumococcal  
vaccine development 
 A one-day workshop 
 
Venue: Liverpool Medical Institute 
Date: Thursday 30th April 2009  
Event webpage: http://idrn.org/events/upcoming/pneumococci.php
 
Organising Committee: Dr Jeremy Brown (UCL), Dr Stephen Gordon (LSTM), 
Michael Head (IDRN), Dr Adam Wright (Biomedical Research Centre, NIHR) 
 
 
Programme 
 
 
Arrival and Registration until 10.15 
 
10.20 Welcome and Introduction 
 
 
10.25 Session 1: Respiratory tract host defence vs pneumococcal carriage and 
disease (Chair: Dr Neil French and Jeremy Brown) 
 
1. Acquired and innate host defence mechanisms in the respiratory tract – 
Known and Unknown (Dr Stephen Gordon, Liverpool School of Tropical 
Medicine) 
2. Dynamics of pneumococcal carriage and host response(s) (Prof. Helena 
Käyhty, National Public Health Institute of Finland) 
3. Mouse models of pneumococcal nasopharyngeal carriage and pneumonia 
- host pathogen interactions (Dr Aras Kadioglu, University of Leicester) 
4. Host Mechanisms for Eradicating Streptococcus pneumoniae Pneumonia 
(Dr Jeremy Brown, UCL) 
5. Dynamics between Virus and pneumococcal infection (Prof Tracy Hussell, 
Imperial College London) 
 
 
12.45 Lunch 
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13.45 Session 2: Pneumococcal therapeutic strategies and correlates of protection 
(Chair: Dr Qibo Zhang and Dr Adam Wright) 
 
1. Pneumolysin - protein antigen and adjuvant (Prof Tim Mitchell, 
University of Glasgow)  
2. Naturally acquired immunity in humans - modelling B & T cell 
responses to vaccine candidates in vitro (Prof Adam Finn, 
University of Bristol) 
3. An in vitro model used to assess effects of nanoparticles on the 
epithelial airway barrier (Dr Martin Clift, University of Bern, 
Switzerland)  
 
 
15.45 Tea and Coffee 
 
 
16.15  Session 3: Translating Pneumococcal Research for Patient Benefit - 
Global and National perspectives (Chair: Dr Stephen Gordon) 
 
1. Biomedical Research Centre Liverpool: Delivering Best Research 
for Best Health in Microbial Diseases (Prof Cheng Hok-Toh, 
Executive Director, Biomedical Research Centre, NIHR) 
2. Protecting vulnerable groups with pneumococcal vaccine (Dr Neil 
French, London School of Tropical Medicine) 
3. Identifying Research priorities Human / Protein / Adult / Child / 
Clinical Trials / Pneumococcus - what research in humans can tell 
us and what is possible with human studies  
 
 
 
18.00  Closing Remarks and post-workshop drinks 
 
 
N.B. Duration of talks: Session 1: 15-20 minutes plus 5 minutes questions 
   Session 2: 20 minutes plus 5 minutes questions 
   Session 3: 20 minutes plus 5 minutes questions 
 
 
 
 
 
 
 
7
 
 
Delegates list 
 
First name Surname Organisation 
Aamir Aslam University of Oxford 
Chris Bailey ImmBio 
Paul Balmer Wyeth Vaccines 
Mathieu Bangert University of Manchester 
HELEN BAXENDALE University College London 
Stephen Bentley Sanger Institute 
Tobias Bexten  
Andrew Boyle Sanofi-Pasteur 
Jeremy Brown University College London 
Isobel Burnett Calderdale and Huddersfield NHS Foundation Trust
Mary Cavanagh Imperial College London 
Bambos Charalambous University College London 
Sue Clarke ImmBio 
Martin Clift University of Bern 
Jonathan Cohen University College London 
Rhett Cooper GlaxoSmithKline 
Jacqui Dawson Wyeth Vaccines 
Sherouk El Batrawy Liverpool School of Tropical Medicine 
Claire Entwisle ImmBio 
Vitor Fernandes University of Leicester 
Daniela Ferreira University of Leicester 
Jamie Findlow Health Protection Agency 
Adam Finn University of Bristol 
Stefan Flasche Health Protection Agency 
Dona Foster University of Oxford 
Linda Franklin University of Leicester 
Neil French London School of Hygiene & Tropical Medicine 
Duncan Fullerton Liverpool School of Tropical Medicine 
Alexandra Godlee Imperial College London 
Upali Goonetilleke Liverpool School of Tropical Medicine 
Stephen Gordon Liverpool School of Tropical Medicine 
John Goulding Imperial College London 
Donna Gray Liverpool School of Tropical Medicine 
Jenna Gritzfeld Liverpool School of Tropical Medicine 
Lucinda Hall Queen Mary's, University of London 
Mike Head Infectious Disease Research Network 
Sue Hill ImmBio 
Samia Hussain University of Leicester 
 
 
8
Tracy Hussell Imperial College London 
Cecilia  Jukka Southport and Ormskirk Hospital NHS Trust  
Aras Kadioglu University of Leicester 
Helena Käyhty National Public Health Institute of Finland 
Mohd. Nadeem Khan  
Alun Kirby University of York 
Maria Koliou Archbishop Makarios Hospital,Nicosia Cyprus 
Marcus Leung University College London 
Jiangtao Ma University of Glasgow 
Carol McInally University of Glasgow 
Paul McNamara Liverpool School of Tropical Medicine 
Tim Mitchell University of Glasgow 
Yaffa Mizrachi NebenzahBen Gurion University, Israel 
Depesh Pankhania University of Leicester 
Jeff Pido University of Bristol 
Caroline Pope University of Bristol 
Ana Porras González University Hospital Virgen del Rocio, Seville Spain 
Elspeth Potton  
Luke Richards University of Leicester 
Kirsty Ross University of Glasgow 
Jens Rueggeberg  GlaxoSmithKline 
Sarah Smeaton University of Leicester 
Andrew Smith University of Glasgow 
Elaine Stanford Health Protection Agency 
Cheng-Hock Toh Liverpool School of Tropical Medicine 
Mark Wilks Queen Mary's, University of London 
Peter Winstanley Liverpool School of Tropical Medicine 
Dan   Wootton  
Adam Wright Liverpool School of Tropical Medicine 
Fatima Wurie Infectious Disease Research Network 
Qibo Zhang Liverpool School of Tropical Medicine 
 
 
 
9
Mucosal Perspectives on pneumococcal disease: A Meeting Summary 
A one-day International workshop focusing on stimulating research and 
collaborations on this topic 
 
Written by Dr Adam Wright, Biomedical Research Centre, NIHR, Royal 
Broadgreen and University Hospitals Livepool 
 
Date: Thurs 30 April 2009 
Location: Liverpool Medical Institute 
Website: http://idrn.org/events/previous/pneumococci.php
 
“Life is short, and Art long; the crisis fleeting; experience perilous and decision 
difficult” Aphorisms of Hippocrates represented on the Liverpool Medical Institute 
crest (Trans. Francis Adams) 
 
Introduction: 
The natural reservoir for Streptococcus pneumoniae (the ‘pneumococcus’) is the 
human nasopharynx and is believed to be a pre-requisite for mucosal (otitis media 
and pneumonia) and invasive disease (Bacteraemia and meningitis) [1].  Recent 
WHO estimates suggest that the pneumococcus is the leading cause for the majority 
of deaths in the under 5 age group worldwide, with the majority of these in sub-
saharan Africa and Asia [2]. 
 
The dynamics between the nasopharyngeal mucosal immune system and microbial 
colonisers such as the pneumococcus need to be understood in order to develop 
reliable markers of vaccine efficacy and protection and also correctly formulate 
mucosal vaccines and/or adjuvants. Due to drawbacks with currently available 
polysaccharide based vaccines, efforts are underway within the research community 
to develop a new, possibly inhaled, vaccine(s) that will utilise pneumococcal proteins 
conserved across different polysaccharide serotypes, together with appropriate 
adjuvants for application into humans [3].  
 
On a wet Thursday morning the doors of the Liverpool Medical Institute were opened 
to mark the opening of the workshop attended by 69 delegates from institutions 
across the UK, Switzerland, Finland, Cyprus, Israel and Malawi.  
 
Proceedings commenced inside the auditorium with a welcome note delivered on 
behalf of the organising committee by Dr Adam Wright (BRC).  Dr Wright 
emphasised the main aim of the day – ‘collaborative discussions’ hoping that the 
workshop would provide a stimulus towards the development of new and exciting 
research collaborations amongst the delegates.  Michael Head (Infectious Disease 
Research Network) subsequently took the lead to highlight the role of the IDRN, 
specifically the promoting and fostering of new and existing collaborations, and the 
stimulation of multi-disciplinary research. In addition Mr Head thanked the sponsors – 
GlaxoSmithKline, Wyeth and Sanofi Pasteur - for their financial support in staging the 
workshop. 
 
Session 1: Dr Stephen Gordon (Liverpool School of Tropical Medicine) 
 
Dr Stephen Gordon opened the workshop.  Pneumococcal epidemiology was 
summarised and particular attention was drawn to the difference between carriage 
and disease.  Carriage precedes disease and is instrumental in transmission; there is 
an excess of both carriage and disease in children and adults with HIV infection.  
Basic mucosal defences against the pneumococcus were outlined and the key 
workshop themes with the speakers who would address these questions introduced: 
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1) The effect of pneumococcal carriage on the host and the effect of the host on 
carriage (i.e. epidemiology of the pneumococcus) (Helena Käyhty and Aras 
Kadioglu) 
2) Understanding infection and host responses using murine models (Aras 
Kadioglu and Jeremy Brown) 
3) Relationship between viral infection and subsequent pneumococcal disease 
(Tracy Hussell) 
4) Vaccine candidates, adjuvants and measuring efficacy (Tim Mitchell, Adam 
Finn and Neil French) 
5) Modelling lung immunity using an in vitro system (Martin Clift) 
 
The remainder of the first talk addressed human studies of mucosal defence against 
the pneumococcus.  Pulmonary defence is critically dependent on cellular and 
humoral defense.  The key phagocyte in pulmonary surveillance is the alveolar 
macrophage [4, 5].  Alveolar Macrophages express receptors that can participate in 
opsonic and non-opsonic phagocytosis.  Opsonic (Fc and complement receptor 3) 
and non-opsonic (MARCO) [6, 7] receptors have been demonstrated to be involved 
in the phagocytosis of the pneumococcus.  Macrophage phagocytosis of opsonised 
pneumococci is intact in HIV infected adults.  There is marked dysregulation of 
macrophage apoptosis in response to pneumococcal challenge and recent work has 
demonstrated the importance of macrophage turnover and efferocytosis in pulmonary 
defence [8].  Future attempts to prevent pneumococcal disease by manipulation of 
the pulmonary mucosal milieu will need to include consideration of the role of the 
alveolar macrophage in regulation as well as defense.   
 
Professor. Helena Käyhty (National institute of Health and Welfare, Helsinki, 
Finland) 
 
Leading on from this Professor Helena Käyhty working at the National institute of 
Health and Welfare presented an update on the PneumoCarr consortium consisting 
of Nine global partners.  The aim of the PneumoCarr consortium is to develop the 
knowledge base and technical guidelines that would allow determination of vaccine 
efficacy to be based upon prevention of pneumococcal nasopharyngeal colonisation.  
It is envisaged that if this aim was to be achieved then prevention of nasopharyngeal 
colonisation could act as a surrogate or alternative benchmark for licensure of 
vaccines.  Prof. Käyhty provided delegates with an authoritative and comprehensive 
account of the dynamics of nasopharyngeal carriage and what we understand about 
the immune response elicited by the host to control it.  Prof. Käyhty suggested that 
there were 109 carriers globally, mostly in children and that one carrier harbours 
greater than 105 organisms at any one time.  Most carriers are likely to harbour inter 
and intra-species variation and some may carry more than one serotype [9], from a 
total pool of 91 serotypes known to date.  Helena presented evidence from two large 
epidemiological data sets (one in Denmark day care centres and the other from The 
Gambia) showing that pneumococci colonisers do not acquire new serotypes as 
readily as individuals who are/have not been colonised.  In addition these studies 
demonstrated that the rate of clearance is similar regardless of the number of 
serotypes carried.  An important caveat highlighted by Prof. Käyhty, however, is the 
sensitivity of the sampling methods employed and the sampling interval.  Prof. 
Käyhty then proceeded to discuss the current data on the immune response to 
carriage.  The current evidence suggests that the elicitation of antibodies, offers 
protection against systemic disease but little protection at the mucosal surface.  
Important work carried out in the US (led by Marc Lipsitch and Richard Malley) [10, 
11] and in the UK by Aras Kadioglu [12] has demonstrated that protective immunity to 
pneumococcal carriage in murine models is mediated by CD4 antigen specific T 
cells, particularly those producing IL-17.  Our understanding of the T cell response to 
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the pneumococcus has grown in recent years in the wake of a better understanding 
of the roles and functions of T cell subsets particularly Interleukin-17 producing T 
helper (Th17) cells.  In humans recent work suggests that there may be similar 
mechanisms of protection against the pneumococcus [10, 13].  More experimental 
human studies need to be undertaken however to verify these interesting findings 
and allow for better vaccine design and choice of adjuvant.  
 
Dr Aras Kadioglu (University of Leicester) 
 
Animal models are important to inform experimental human studies and for the 
design of vaccines.  Dr Kadioglu has set up mouse models to address questions 
relating to pneumococcal colonisation and acute or chronic mucosal infection. These 
models are used to provide information on the contribution made by individual 
pneumococcal virulence proteins towards establishing colonisation/infection and also 
on the host immune response at a given in vivo locality.  Dr Kadioglu pointed out that 
the contribution of individual pneumococcal virulence factors (and thus the immune 
response) towards colonisation/infection differs individually and collectively and is 
dependent on the in vivo location of the bacterium and host genetics [14, 15].  Dr 
Kadioglu presented new data showing the establishment of long-term asymptomatic 
pneumococcal nasopharyngeal carriage in a mouse model that was followed for a 
period of 28 days.  To maintain carriage, pneumococcal pneumolysin is important 
since without it the host is able to clear nasopharyngeal carriage within 7 days.  Dr 
Kadioglu subsequently highlighted other pneumococcal proteins that also contribute 
to colonisation/infection [16] before focusing on the role of PavA (pneumococcal 
adherence and virulence factor A).  Dr Kadioglu presented interesting new data 
demonstrating the importance of Pav A for long-term asymptomatic nasopharyngeal 
carriage and its role in translocation across host tissue barriers during bacteraemia. 
The mechanism of PavA virulence is currently under further investigation. 
 
Dr Jeremy Brown (University College London) 
 
The discussion subsequently turned its focus away from the pneumococcus and 
towards the host immune response. Dr Brown provided an overview of the immune 
mechanisms that may provide protective immunity early and late in the course of lung 
infection and highlighted the multi-factorial nature of the host response to the 
pneumococcus.  In contrast to Dr Gordon’s discussion on the role of immunoglublin, 
Dr Brown also emphasised the role of complement as a mediator of the innate and 
adaptive immune response through opsonising the pneumococcus for uptake by 
macrophages.  Given the relatively low concentrations of complement present in 
alveolar lining fluid it remains to be established what role complement plays in human 
lung mucosal immunity against pneumococci.  The effect of complement is likely to 
vary between individuals and different pneumococcal isolates and these may be 
factors influencing susceptibility to pneumococcal infection.  
 
Following phagocytosis macrophages are able to act as ‘gate-keepers’ of the 
immune response by initiating pro-inflammatory responses such as tumour necrosis 
factor in response to a large bacterial challenge, or having an anti-inflammatory effect 
in response to a smaller bacterial challenge through apoptosis [4, 5, 8].  Dr Brown 
highlighted studies demonstrating the importance of defective signalling pathways of 
the Toll-like receptors (TLR) for protection of both mice and humans against 
pneumococcal infections [17].  The lung inflammatory response to the 
pneumococcus results in phagocyte recruitment, with a marked influx of neutrophils 
and monocytes into the lungs.  Neutrophils are able to phagocytose pneumococci 
and this is also largely complement-dependent, but the speaker reminded delegates 
that the role of the neutrophil is uncertain since patients with either chronic 
granulomatous disease or neutropenia have only a moderate increase risk of 
pneumococcal infection.  Other protective mechanisms that have come to light 
recently include the role of the Th17 subset, which have been shown to be important 
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for acquired immunity to nasopharyngeal colonisation with the pneumococcus and 
may have a similar role against lung infection [11].  T cell function (CD4 and CD8) 
could be important for future vaccine strategies since they can provide immunological 
memory if stimulated appropriately, and these memory responses can be measured 
using whole blood or cells isolated from the respiratory tract.  Dr Brown concluded 
that different immunological protective mechanisms operate at different stages of 
pneumococcal colonisation and infection.  It is currently unclear whether an 
intervention to eradicate colonisation or prevent mucosal infection in the lungs would 
be the best strategy.  Aiming to alter the microbial flora of the nasopharynx to 
eradicate the pneumococcus may not be beneficial, as the recent introduction of the 
conjugated vaccine has demonstrated that strains not eradicated by the vaccine can 
quickly refill the ecological niche. 
 
Professor Tracy Hussell (National Heart and Lung Institute, Imperial College 
London) 
 
On the topic of lung immunity we were reminded by Professor Tracy Hussell of the 
site specific immunoregulatory mechanisms that are in place to prevent over 
exuberant pro-inflammatory immune responses within the lung.  Overcoming such 
mechanisms by short term stimulation is a challenge to the design and application of 
protein based anti-pneumococcal vaccines within the lung.  Further challenges 
include the impact concomitant viral infection and the role an anti-viral response may 
play towards predisposing towards pneumococcal infection.  Prof. Hussell discussed 
the ‘immune rheostat’ concept whereby ‘brightening’ and ‘dampening‘ pathways 
operate concomitantly to regulate innate immune activation within the lung.  In this 
area Prof. Hussell demonstrated the important role of CD200 expressed by T cells 
and epithelial cells and its interaction with its receptor found at high levels on alveolar 
macrophages and granulocytes [18].  Ligation of CD200R with its ligand can 
attenuate pro-inflammatory cytokine production by macrophages.  Recently it has 
become increasingly apparent that not only can innate immunity halt pro-
inflammatory mechanisms mediated by adaptive immune cells but the converse is 
also true [19].  Elucidating the regulatory mechanisms of this bi- or even multi -
directional feedback loop will provide an important framework for the testing of 
vaccine adjuvants.  As an important caveat to this Prof. Hussell highlighted the 
dangers of sub-optimally adjusting mucosal immunity. 
 
Prof. Hussell provided a prescient reminder of dysregulated mucosal defences using 
epidemiology data from the 1918-1919 influenza pandemic.  This demonstrated that 
subsequent bacterial pneumonia due to the pneumococcus was a major cause of 
mortality [20].  The recent identification of swine flu infected persons in Mexico and 
the speed with which global transmission of disease can occur was a timely 
demonstration on the importance of this topic.  Using murine models of infection Prof. 
Hussell demonstrated that viral infection for three days prior to bacterial infection 
resulted in an inability of the host to reduce the bacterial burden in the airways 
culminating in a much earlier death.  The immune response following viral challenge 
was still compromised 4-6 weeks later since pneumococcal challenged mice had 
impaired clearance of airway and lung bacteria.  The immune profile following a 
previous infectious episode can have an important bearing on subsequent immune 
responses to infection or vaccine application as Prof. Hussell and other groups have 
demonstrated [21]. Biomarkers may thus have to be developed to ensure that a 
deleterious or ineffectual immune response will not ensue following vaccine 
administration.  An example of this could be the levels of CD200R on macrophages.  
Here Prof. Hussell noted that 14 days post-viral infection there was a higher basal 
level of CD200R expression on alveolar macrophages suggesting a heightened 
threshold for triggering of an immune response.  Clearly further research is required 
in this area.   
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Session 2: Professor Tim Mitchell (University of Glasgow) 
 
The second session, chaired by Dr Adam Wright and Prof. Qibo Zhang, moved away 
from the host-pathogen interaction and towards vaccine candidates and measuring 
immune responses following vaccine administration.  Professor Tim Mitchell provided 
an interesting talk regarding the use of the pneumococcal virulence factor 
pneumolysin as a candidate protein vaccine and adjuvant.  The advantages of using 
pneumolysin are that it is a conserved protein, expressed by all invasive serotypes 
and it plays an important role during pneumococcal colonisation/infection [16].  Prof. 
Mitchell emphasised the important caveats to this, which include its cytotoxicity to 
mammalian cells and that on its own it can reproduce pneumococcal disease 
symptoms in murine lungs.  For this reason (and to understand pneumolysin biology) 
non-toxic forms (∆6) have been developed to abrogate its toxicity towards 
mammalian cells.  A vaccine composed of a fusion of ∆6 and capsular serotype 4 
gave full protection (measured as survival and bacterial load) to mice challenged 
intra-peritoneally with a serotype 4 pneumococcal strain compared to either alone.  
The fusion of ∆6 or its wild type counterpart –pneumolysin – to known pneumococcal 
virulence proteins for use as a vaccine is an attractive avenue of research that is 
currently being pursued in his laboratory.  Pneumolysin can thus act as an adjuvant 
and antigenic target.  In line with this, Prof. Mitchell was able to demonstrate good 
mucosal IgA responses following vaccination of mice with fusion proteins compared 
to single administration. 
 
Five pneumococcal antigens (PsaA, PspA, PspC, PhtD and Mixture) are part of a 
PATH project to find the best fusion mixture that would give the best protection in 
murine models of pneumococcal colonization and pneumonia.  Vaccines based on 
single conserved pneumococcal proteins have elicited protective responses from 
mice however this could ultimately be improved by conjugating several together.  In 
addition, for a mucosal application, an adjuvant will be necessary given the 
immunoregulatory mechanisms that exist, as pointed out by Prof. Hussell, at the 
mucosal surface.  A non-toxic version of pneumolysin would be ideal.  Current 
limitations appear to be confined to highlighting appropriate antigens and chemically 
coupling them together.  Prof. Mitchell stressed that this work is in a very early stage.  
One fusion protein that is undergoing evaluation is PsaA-PLY.  Intranasal 
administration of PsaA-∆6 or PsaA-PLY into mice elicited 10-100-fold more PsaA 
specific IgG, respectively, compared to PsaA alone.  These early studies suggest 
that the PsaA-∆6 construct is more effective than PsaA alone but 50% less than that 
carrying the wild type pneumolysin protein.  Reducing the gap in effectiveness 
between fusion contructs would be an important step towards producing an effective 
construct for human trials.  Important questions that generated debate were ‘Which 
protein(s)?’ and ‘What type of response(s)?’  One pertinent question was what is the 
next step to take these protein constructs closer into humans?  
 
Professor Adam Finn (University of Bristol) 
 
The focus subsequently shifted from the composition of new vaccines to modulation 
of the immune response by adjuvant, e.g. bacterial lipoproteins, delivered by Prof. 
Adam Finn from Bristol.  Bacterial lipoproteins are Toll-like receptor 2 agonists and 
their effect on pneumococcal specific memory and naive adenoidal B and T cell 
responses were discussed.  They demonstrated that adenoidal mononuclear cells 
from pneumococcal culture positive children produce high levels of anti-
pneumococcal protein antibodies when stimulated (“memory response”) with 
pneumococcal proteins.  In contrast antigen specific immunoglobulin towards the 
pneumococcus could not be detected in the culture supernatant of the adenoidal 
mononuclear cells from approximately half of the culture negative children (“Naive 
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response”).  The next question was whether trace amounts of antigen specific 
immunoglobulin could be increased if adenoidal mononuclear cells were stimulated in 
the presence of a TLR 2 agonist.  Interestingly, whilst the naive responses increased 
dose dependently with TLR 2 agonist concentration, memory responses declined by 
over half setting up an interesting dichotomy.  This outcome was also reflected in 
memory T cell proliferation data.   Here proliferation of antigen specific CD45RO T 
cells declines in the presence of a TLR 2 agonist whereas the proliferation of 
CD45RO depleted cells (i.e. naive cells) increases.  Professor Finn provided 
evidence that increased IL-10 production and ICOS expression may be down-
regulating this memory response via production from antigen presenting cells and 
expression on T cells, respectively.  Drawing on data presented earlier in the day 
particularly that demonstrated by Prof. Hussell, TLR 2 agonists may be a useful tool 
to return the immune rheostat following viral infection or vaccination towards its 
normal anti-inflammatory homeostatic state to prevent unwanted inflammation.  It 
was made clear that more information about immune regulatory mechanisms in 
health and disease is required prior to attempting to modulate responses via 
adjuvants but nevertheless it has provided us with some useful insights. 
 
Dr Martin Clift (Institute of Anatomy, University of Bern) 
 
Dr Martin Clift wrapped up the post-lunch session with an entertaining and 
informative presentation on the effect of nanoparticles (NPs) on the epithelial airway 
barrier.  Martin offered two definitions of what constituted a nanoparticle: 1) particles 
with at least one dimension <100nm [22] and 2) a nano-object (a material with one, 
two or three external dimensions in the nanoscale) with all three dimensions in the 
nanoscale1 and further described how the Institute of Anatomy, at the University of 
Bern, have constructed an in vitro model of the epithelial airway barrier.  The model, 
presented by Dr Clift, is the culmination of work in the laboratory of Dr Barbara 
Rothen-Rutishauser and Professor Peter Gehr.  The triple cell co-culture model 
reflects three different cell types of the epithelial airway barrier; 1) airway epithelial or 
bronchial cells forming the membrane barrier, 2) monocyte derived dendritic cells 
attached to the basal side and 3) monocyte derived macrophages which were 
located on the luminal side [23].  Although alternative in vitro co-culture systems of 
the lung exist [24], the model by Dr Rothen-Ruthishauser reflects exactly the in vivo 
juxtaposition of cells as well as takes into consideration the interaction and 
cumulative cellular responses rather than examining the response of single cell 
types.  In addition to the in vitro co-culture, collaboration with the Helmholtz Centre in 
Munich, Germany, has enabled the Institute of Anatomy to further research the effect 
of NPs at the air-liquid interface via forming aerosols which are delivered onto the 
triple co-culture system.  These developments are extremely interesting since if 
translational science is to be successful then not only are good animal models 
required but also an improvement and refinement in laboratory human models that 
closely reflect interactions in vivo are also required.  The pipeline of promising animal 
vaccine research to early phase human trials can then increase with the aim of 
improving patient care.  The triple cell co-culture model is currently being used to 
evaluate the potential harmful effects of NPs on the epithelial airway barrier.  
Although much is known as to the harmful effects of nanoparticulates contained 
within air-pollution (formed from processes such as exhaust fumes) it is not yet clear 
what the full effects are following exposure to these accidental NPs. Also, at this 
moment in time, it is unclear whether manufactured NPs, such as those intended for 
use as medical applications, have deleterious effects on human health and the 
environment.  Dr Clift and his colleagues at the Institute of Anatomy in Bern, as well 
as their world-wide collaborators, are currently researching these many aspects in 
 
1 International Standards Organisation (ISO) Technical Specification (ISO/TS) 27687; 
Nanotechnologies – Terminology and definitions for nano-objects – Nanoparticle, nanofibre and 
nanoplate; First published 2008-08-15. 
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order to provide information as to the potential harmful effects that could occur 
following exposure to NPs, and subsequently what the consequences of these 
exposures could be following NP/cell interaction.  
 
Session 3: 
 
Professor Cheng-Hok Toh (Biomedical Research Centre, NIHR) 
 
Professor Cheng-Hok Toh briefly took the stage to describe the exciting 
developments occurring in Liverpool as one of the few Biomedical Research Centres 
(BRCs) in the UK.  BRCs arose from the conclusion of the Cooksey review 
(December 2006) for the House of Commons Science and Technology select 
committee.  The review highlighted insufficient translation of basic into applied 
research culminating in insufficient applied research to meet health needs.  The NHS 
along with University and industry forms a central part to the increased output of 
translational research.  This has been exemplified by many of the discussions held 
today, which have shown the current extent of inter-institutional co-operation. 
Professor Toh covered some of the strengths of the Liverpool bid and the themes, 
which Liverpool are leading on.  The four themes based at Liverpool include 1) 
Safety of anti-microbials 2) Sexual Health 3) Community and Hospital Inquired 
Infections and 4) Pulmonary Infections.  These themes are measured against 
milestones to assess progress by an external advisory panel.  Finally Prof. Toh 
highlighted the clinical research facility and repository that has recently been set up 
within the Liverpool Hospitals NHS trust, University of Liverpool and Liverpool School 
of Tropical Medicine.  His take home message was that Liverpool and the BRC are 
ready to take on the challenges to meet the local and global health needs of the 21st 
century. 
 
Dr Neil French (London School of Hygiene and Tropical Medicine) 
 
The aim of the final session was to get an insight into pneumococcal vaccination “in 
the field” kindly delivered by Dr Neil French who had travelled to the workshop from 
Malawi.  Subsequently there was an open floor discussion about the next steps that 
need to be taken to reach the goal of protecting vulnerable groups of pneumococcal 
mucosal disease here in the UK and overseas.  Dr French highlighted the push by 
advocacy groups to introduce seven, ten and thirteen valent pneumococcal 
conjugate vaccines (PCV-7, 10, 13) to vulnerable groups mostly in sub-saharan 
Africa and Asia. Dr French subsequently provided evidence that PCV-7 has showed 
efficacy in protecting against invasive and mucosal disease in target groups (e.g. HIV 
infected Malawians). 
Returning to the theme covered by Prof. Mitchell earlier in the day, new vaccines are 
required to surmount limited serotype coverage, limited protection at mucosal sites 
and durability posed by the current conjugate vaccines.  Dr French discussed the 
challenges that are presented when introducing a new vaccine particularly those not 
based on pneumococcal capsule and when no in vitro correlate of immunity can be 
used as a surrogate.  A randomised control trial will be necessary however it is 
unclear what is an appropriate control and end-point? Is the sample size attainable 
particularly when comparing with the current gold standard of a multivalent protein 
conjugate capsular vaccine? What end-points should be measured clinically and 
immunologically? How will the immunological endpoints be confounded by carriage? 
Hopefully PneumoCarr will be able to shed light on these latter topics and we look 
forward to hearing about their work at future meetings such as the International 
Symposium on pneumococci and pneumococcal disease to be held in Israel in 2010 
(ISPPD-7). 
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Discussion Session – Chair Dr Stephen Gordon 
 
Dr Gordon asked all of the speakers to return to the front of the audience for their 
thoughts on some of the challenges facing mucosal pneumococcal research and to 
answer any questions from the audience.  The panel included John Goulding 
(representing Prof. Hussell), Dr Martin Clift, Dr Neil French, Prof. Helena Käyhty, 
Prof. Tim Mitchell and Dr Aras Kadioglu.  The aim of this session was to identify 
areas of the host immune response and pneumococcal biology that require further 
study.  It was noted that there are some important questions regarding the host-
bacterium relationship that require consideration in the development of a mucosal 
vaccine including: 
a) What is the population size for the pneumococcus at the nasopharynx during 
health and during invasive disease?  
b) What are the consequences of ‘good’ mucosal immunity? 
c) What are the contributors for the transition from a ‘harmless’ coloniser to 
invasive disease? 
 
A lively discussion ensued on this latter topic highlighting the multi-factorial and 
dynamic nature of the host- opportunistic pathogen relationship.  Possible 
contributing factors included the initiation of biofilm formation (how important is this 
process to disease formation in humans? Should more attention be directed towards 
it?), contribution made by co-coloniser strains/serotypes not usually assessed? 
Which contributes more the genetics of the host or the pneumococcus?  
 
Questions posed by the workshop included: 
 
• What human experimental medicine studies are required that will translate 
basic pneumococcal research for patient benefit?  
• Should the aim of new vaccines be the prevention of carriage?  
• What are the consequences of reduced pneumococcal carriage?  
• Which pneumococcal proteins should be taken forward for a mucosal 
vaccine? 
• Which adjuvant and what is the most appropriate response?  
• How do we evaluate new (probably protein) vaccines against the current 
‘gold-standard’? 
 
To sum up this final session the chair person asked the speakers what would be their 
ideal project.   
From this the following themes emerged:  
• A greater multi-disciplined approach between microbiologists and 
immunologists whilst tracking a single pneumococcus and its interaction 
within the nasopharynx 
• A full Genomic approach directed towards the pneumococcus during the 
transition between colonisation and infection.   
• What are the effects of nano-particle exposure on predisposing to subsequent 
colonisation and infection. 
• How protein vaccines work with the aim of developing functional lab 
immunological assays to determine efficacy following administration 
Clearly there are many unanswered questions on this topic and it is hoped that over 
the coming years light shall be shed on these important questions.  
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